Anti-Cancer Activity of PAK4/NAMPT Inhibitor and Programmed Cell Death Protein-1 Antibody in Kidney Cancer

Josephine F. Trott,1 Omran Abu Aboud,1 Bridget McLaughlin,2 Katie L. Anderson,3,4,5,6 Jaime F. Modiano,3,4,5,6,7 Kyoungmi Kim,8 Kuang-Yu Jen,9 William Senapedis,10 Hua Chang,10 Yosef Landesman,10 Erkan Baloglu,10 Roberto Pili,11 and Robert H. Weiss1,2,12

Abstract

Background Kidney cancer (or renal cell carcinoma, RCC) is the sixth most common malignancy in the United States and is increasing in incidence. Despite new therapies, including targeted therapies and immunotherapies, most RCCs are resistant to treatment. Thus, several laboratories have been evaluating new approaches to therapy, both with single agents as well as combinations. Although we have previously shown efficacy of the dual PAK4/nicotinamide phosphoribosyltransferase (NAMPT) inhibitor KPT-9274, and the immune checkpoint inhibitors (CPI) have shown utility in the clinic, there has been no evaluation of this combination either clinically or in an immunocompetent animal model of kidney cancer.

Methods In this study, we use the renal cell adenocarcinoma (RENCA) model of spontaneous murine kidney cancer. Male BALB/cJ mice were injected subcutaneously with RENCA cells and, after tumors were palpable, they were treated with KPT-9274 and/or anti-programmed cell death 1 (PDCD1; PD1) antibody for 21 days. Tumors were measured and then removed at animal euthanasia for subsequent studies.

Results We demonstrate a significant decrease in allograft growth with the combination treatment of KPT-9274 and anti-PD1 antibody without significant weight loss by the animals. This is associated with decreased (MOUSE) Naprt expression, indicating dependence of these tumors on NAMPT in parallel to what we have observed in human RCC. Histology of the tumors showed substantial necrosis regardless of treatment condition, and flow cytometry of antibody-stained tumor cells revealed that the enhanced therapeutic effect of KPT-9274 and anti-PD1 antibody was not driven by infiltration of T cells into tumors.

Conclusions This study highlights the potential of the RENCA model for evaluating immunologic responses to KPT-9274 and checkpoint inhibitor (CPI) and suggests that therapy with this combination could improve efficacy in RCC beyond what is achievable with CPI alone.

Introduction

Recent advances in immunotherapy have revolutionized the field of cancer treatment. Using antibodies against programmed cell death 1 (PDCD1; PD1) and/or PD1 ligand 1 (CD274; PD-L1) to block the inhibition on immune recognition of tumor cells (i.e., immune checkpoint) results in clearance of a wide range of tumor types by T cells (1). Specifically, immune checkpoint inhibitors (CPIs) have shown promise in multiple clinical trials of patients with renal cell carcinoma (RCC) with objective response rates of 12%–31% (2). Unfortunately, in patients with RCC, complete responses to a single PD1/PD-L1 antibody in the absence of an accompanying conventional or targeted therapeutic are rare (2). For this reason, many clinical researchers are investigating the treatment of RCC using combinations of CPI with angiogenesis inhibitors (2) or with targeted agents.

1 Division of Nephrology, Department of Internal Medicine, University of California, Davis, California
2 Comprehensive Cancer Center, University of California, Davis, California
3 Animal Cancer Care and Research Program, College of Veterinary Medicine, University of Minnesota, St Paul, Minnesota
4 Department of Veterinary Clinical Sciences, College of Veterinary Medicine, University of Minnesota, St Paul, Minnesota
5 Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota
6 Stem Cell Institute, University of Minnesota, Minneapolis, Minnesota
7 Division of Biostatistics, Department of Public Health Sciences, University of California, Davis, California
8 Department of Pathology and Laboratory Medicine, University of California, Davis, California
9 Research and Translational Development, Karyopharm Therapeutics Inc., Newton, Massachusetts
10 Simon Cancer Center, School of Medicine, Indiana University, Indianapolis, Indiana
11 Medical Service, Veterans Affairs Northern California Health Care System, Sacramento, California

Correspondence: Dr. Josephine F. Trott, Department of Animal Science, 450 Bolelli Way, University of California, Davis, CA 95616. Email: jftrott@ucdavis.edu
KPT-9274 is an orally bioavailable, small molecule that modulates the activities of both p21 (RAC1) activated kinase 4 (PAK4) and nicotinamide phosphoribosyltransferase (NAMPT) (3). KPT-9274 reduces the steady-state level of PAK4 in breast cancer cells (4) and kidney cancer cell lines (3). KPT-9274 has also been shown to have potent antitumor activity in murine xenograft models, including RCC (3–10), and in trials of companion dogs with lymphoma (11). KPT-9274 is currently in a phase 1 study (NCT02702492) to assess the safety, tolerability, and preliminary efficacy in patients with advanced solid malignancies or non-Hodgkin lymphoma (NCT02702492) (12).

NAMPT catalyzes the rate-limiting step in the main salvage pathway used to produce oxidized beta-nicotinamide adenine dinucleotide (NAD+), an essential coenzyme in energy-producing catabolic reactions (13). In vertebrates, NAD+ can be synthesized de novo from tryptophan or salvaged from nicotinamide (through NAMPT), nicotinic acid (through nicotinate phosphoribosyltransferase, NAPRT), or nicotinamide riboside (through nicotinamide riboside kinase) (4,13). Cancer cells preferentially generate NAD through nicotinamide and NAMPT, most likely because de novo NAD+ synthesis occurs predominately in the liver and NAPRT is often epigenetically downregulated in cancer cells through hypermethylation of the NAPRT promoter (found in 5%–65% of samples tested, depending on tumor type). This correlates with low NAPRT expression in these lines and tumor samples (14). We have previously shown that two human RCC cell lines have very low levels of NAPRT expression, and treatment with KPT-9274 reduces proliferation and induces apoptosis in these cells (3). Additionally, a selective inhibitor of NAMPT (FK866/APO866) was found to have antitumorigenic, antimetastatic, and antiangiogenic activity in a syngeneic mouse model of renal cell adenocarcinoma (RENCA) (15).

The signaling molecule PAK4 is involved in multiple pathways, including WNT/β-catenin signaling (16), whose target genes include CCND1 and MYC (17), both of which have key roles in cell proliferation (18). PAK4 regulates the activity of CDKN1A (p21) and thereby regulates normal progression of the cell cycle (19). PAK4 has also been implicated in the oncogenic transformation of cells (20,21). In a recent publication, the epithelial-to-mesenchymal transition (EMT) of gastric cancer cell lines was correlated to the loss of NAPRT expression (22). The authors suggested that NAPRT expression destabilizes β-catenin and acts as a tumor suppressor protein prior to the cells undergoing the EMT phenotypic change. However, when NAPRT is lost through the dynamic process of epigenetic silencing (possibly through selective pressure on cancer cells), β-catenin is stabilized, resulting in the activation of an EMT program in these cell lines. At the same time, the EMT cells become sensitive to NAMPT inhibition (22). PAK4 also affects β-catenin stability by inhibiting degradation of β-catenin (16,23).

Recently, a correlation was reported between activation of the PAK4 and WNT/β-catenin signaling pathway and T cell exclusion in samples of patients with melanoma (24,25). The low immune cell infiltration is also associated with resistance to PD-L1/CTLA4 antibody therapy (24). This correlation has been further validated in other cancer types including breast, colorectal, non-small cell lung, and RCC (26), and these data suggested that combination therapies in which activated β-catenin is inhibited simultaneously with targeting PD1, as we have investigated in this study, may be particularly effective. Thus, PAK4/WNT/β-catenin, NAMPT, and the immune system seem to converge, making KPT-9274 and immune CPI combination a viable therapy for patients with RCC.

In this study, we show that PD1 inhibition enhances the antitumor effect of the novel RCC therapeutic KPT-9274, which specifically targets tumors they have used to metabolic reprogramming of the NAD+ biosynthesis pathway. Thus, combination immunotherapies using dual PAK4/NAMPT inhibition as well as CPI antibodies are now primed to be studied in the oncology clinic.

Materials and Methods

Tissues and Cells

Mouse RENCA-luciferase (RENCA-luc) cells were derived from a spontaneous kidney adenocarcinoma in BALB/cCr mice (27–29), and were authenticated by short tandem repeat and species analysis (IDEXX BioAnalytics, Colombia, MO). They were injected into mice at passage 29, and were authenticated by ATCC and passaged <20 times. All cells were confirmed mycoplasma-free and were handled one at a time in the cell culture hood, each with their own media and trypsin bottle. Tissues from human clear cell RCC (ccRCC) tumors and normal human kidney tissues (adjacent to a tumor) were archived following Institutional Review Board approval at the Department of Pathology, University of California, Davis (UC Davis).

In Vivo Experiments

Animal experiments were performed in accordance with guidelines set forth by the Institutional Animal Care and Use Committee at UC Davis. Male BALB/c mice (Jackson Laboratories, Bar Harbor, ME) that were 6 weeks old had ad libitum access to standard laboratory mouse chow and water. RENCA-luc cells (2.5×10⁶) were injected into 100 μl of OptiMEM with 33% BD Matrigel Matrix (Corning, Tewksbury, MA) subcutaneously in the right flank of male mice when they reached 8 weeks of age. Male mice were used because RCC is more severe and twice as common in men as in women (30). Treatments were started 10 days after injection. Four separate batches of mice were injected with RENCA-luc cells and then treated. Treatments were assigned randomly to mice within each batch. Anti-mouse PD1 or isotype control antibody (250 μg/dose) was injected intraperitoneally twice a week. KPT-9274 (200 mg/kg) or vehicle was administered orally twice a day, 5 days per week. Mice were weighed at the start of the treatment period and once a week thereafter. Subcutaneous tumors were measured (length and width) in situ every 2–3 days using calipers, and tumor volume was calculated using the equation V = 4/3π×(length/2) × (width/2) × (depth/2). Tumors were dissected and a small piece was frozen, a second small piece was fixed in 10% formalin for histology and
immunohistochemistry, and the remainder was processed for flow cytometry. Spleens were also harvested, either for flow cytometry or for fixation in 10% formalin.

**Immunohistochemistry**

Formalin-fixed, paraffin-embedded sections (5 μm) were cut from untreated BALB/c mouse RENCA tumors. Immunohistochemistry was performed as previously described (31) using the following antibodies: Ki67 (275R-18; Cell Marque), PD-L1 (13684; Cell Signaling Technology, Danvers, MA), and programmed cell death 1 ligand 2 (PD-L2) (82723; Cell Signaling Technology).

**Isolation of Tumor-Infiltrating Cells and Flow Cytometry**

Tumors and spleens were harvested, mashed against a size 60 mesh stainless steel screen (Sigma-Aldrich), and a size 60 mesh stainless steel screen (Sigma-Aldrich), and cells were stained in staining buffer (PBS, 3.5% FBS, 1 mM EDTA) with a panel of anti–nordre Laboratories) and cells were stained in staining with Zombie Aqua (Biolegend). Nonspecific staining was blocked using mouse γ-globulin (Jackson ImmunoResearch Laboratories) and cells were stained in staining buffer (PBS, 3.5% FBS, 1 mM EDTA) with a panel of antibodies purchased from Biolegend, except where indicated: anti–CD45-Alexa Fluor 700 (clone 30-F11), anti–CD4–PE (clone RM4-), anti–CD19–FITC (clone 6D5), anti–CD3–FITC (clone CD3D5), anti–CD4–PE/Cy7 (clone M1/70), anti–CD11b–APC/Fire 750 (clone M1/70), anti–CD4–PE (clone RM4-), anti–CD19–FITC (clone 6D5), anti–CD3–FITC (clone CD3D5), anti–CD4–PE/Cy7 (clone M1/70), anti–CD11b–APC/Fire 750 (clone M1/70), anti–CD4–PE (clone RM4-), anti–CD19–FITC (clone 6D5), anti–CD3–FITC (clone CD3D5), anti–CD4–PE/Cy7 (clone M1/70), anti–CD11b–APC/Fire 750 (clone M1/70), anti–CD4–PE (clone RM4-), anti–CD19–FITC (clone 6D5), anti–CD3–FITC (clone CD3D5), anti–CD4–PE/Cy7 (clone M1/70), anti–CD11b–APC/Fire 750 (clone M1/70), anti–CD4–PE (clone RM4-), anti–CD19–FITC (clone 6D5), anti–CD3–FITC (clone CD3D5), anti–CD4–PE/Cy7 (clone M1/70), anti–CD11b–APC/Fire 750 (clone M1/70), anti–CD4–PE (clone RM4-), anti–CD19–FITC (clone 6D5), anti–CD3–FITC (clone CD3D5), anti–CD4–PE/Cy7 (clone M1/70), anti–CD11b–APC/Fire 750 (clone M1/70), anti–CD4–PE (clone RM4-), anti–CD19–FITC (clone 6D5), anti–CD3–FITC (clone CD3D5), anti–CD4–PE/Cy7 (clone M1/70), anti–CD11b–APC/Fire 750 (clone M1/70), anti–CD4–PE (clone RM4-), anti–CD19–FITC (clone 6D5), anti–CD3–FITC (clone CD3D5), anti–CD4–PE/Cy7 (clone M1/70), and programmed cell death 1 ligand 2 (PD-L2) (82723; Cell Signaling Technology).

**RNA Extraction, Reverse Transcription, and Quantitative PCR**

RNA extraction, reverse transcription, and quantitative PCR (qPCR) were performed as previously described (32,33). Primer sequences, annealing temperatures, and efficiency of amplification for NAMPT, NAPRT, Nampt, and Naprt are in Table 1. The (HUMAN)NAMPT primers amplify 9 potential transcripts including the full-length protein coding transcript. The (HUMAN)NAPRT primers amplify 11 potential transcripts including the full-length protein coding transcript. The (MOUSE)Nampt and Naprt primers amplify the single protein coding transcript in each case.

**Immunoblotting**

Immunoblotting was performed as previously described (38). Briefly, tumors and kidneys were homogenized in T-PER buffer (ThermoFisher Scientific). Polyanlydine difluoride membranes were blocked in 5% milk and probed with appropriate primary and secondary antibodies. Signal was detected with enhanced chemiluminescence using either a Fuji Imager, or x-ray film and ImageJ to quantify band intensity. Phospho-β-catenin and PAK4 antibodies (Cell Signaling Technology) were probed at 1:1000. Rabbit anti-NAMPT (Bethyl Laboratories, Montgomery, TX) was probed at 1:2000. Rabbit polyclonal anti-NAPRT (PA5-70595; ThermoFisher Scientific) was probed at 1:500. Mouse anti–β-actin (Sigma-Aldrich) was probed at 1:4000. Rabbit anti–β-actin (Cell Signaling Technology) was probed at 1:2000.

**Oxidized and Reduced β-Nicotinamide Adenine Dinucleotide Assay**

Total oxidized (NAD+) and reduced β-Nicotinamide adenine dinucleotide (NADH; NAD+ + NADH) was quantified in tumor extracts using the NAD/NADH Glo Assay kit.

### Table 1. PCR primers used for quantitative PCR

| Gene | Accession Number | Forward Primer (5’–3’) | Reverse Primer (5’–3’) | Tm (°C) | E (%) |
|------|------------------|------------------------|------------------------|---------|-------|
| (HUMAN)NAMPT (34) | | GCAGAAGCCCGAG | TGTCTGTGGGTGGATATTG | 64 | 98 |
| (HUMAN)NAPRT<sup>a</sup> | NM_145201.5 | TCCCTGGGTGGCG | TGTCTGTGGGTGGATATTG | 64 | 96 |
| (MOUSE)Nampt (35) | | TCTATAA | AAGTTCCCCTGTTGGTCTCA | 66 | 81 |
| (MOUSE)Naprt<sup>a</sup> | NM_172607.3 | TCGGTCTGTGGTGCG | TGT | 60 | 86 |
| Rpl13a (33) | | AGAGGCGCAT | TCCAGTACAAAAAGCACCAC | 60 | 86 |
| Eef2 (33) | | CAGCC | AAGTG | 66 | 92 |
| RNA18S5&18S (36) | | TCCAGTACAAAAAGCACCAC | TCGAG | 66 | 80 |
| PPIA (37) | | GCAGAAGCCCGAG | TGTCTGTGGGTGGATATTG | 64 | 83 |

Tm, annealing temperature; E, efficiency of amplification.

<sup>a</sup>PCR products confirmed by sequencing.
(Promega) following the manufacturer’s instructions. Briefly, 10–30 mg of tumor tissue was homogenized in 1–5 ml of a 50:50 mixture of PBS, pH 7.4, and bicarbonate base buffer with dodecyltrimethylammonium bromide (DTAB; Sigma-Aldrich) (1% DTAB, 100 mM sodium carbonate, 20 mM sodium bicarbonate, 10 mM nicotinamide [Sigma-Aldrich], 0.05% Triton X-100). Four dilutions of the tumor homogenates were assayed against a standard curve of NAD+ (Sigma-Aldrich), prepared in a 50:50 mixture of PBS/bicarbonate base buffer with DTAB (0–400 nM). NAD+ NADH values were normalized to protein concentrations that were measured using the DC Protein Assay (Bio-Rad).

Thiazolyl Blue Tetrazolium Bromide Assay
Cells (1.4×10^5) were plated in 96-well plates and the next day KPT-9274 was added to fresh media in a range of concentrations (0–10 μM). Three days later, cells were stained with Thiazolyl Blue Tetrazolium Bromide as previously described (39).

Bisulfite Genomic DNA Modification, Methylation-Specific PCR, and Quantitative Methylation-Specific PCR
Genomic DNA (gDNA) was extracted from ccRCC tumors; RENCA tumors (untreated mice); normal kidneys (human and BALB/cJ mice); and the RCC cell lines Caki-1, 786-O, and ACHN. Each human gDNA sample (1 μg) was methylated using CpG Methylation transferase following the manufacturer’s instructions (New England Biolabs, Ipswich, MA). For each human sample, an equal mass of both 100% methylated gDNA and untreated gDNA (range of 376–826 ng) were bisulfite converted along with mouse gDNA (500 ng) using the Zymo EZ DNA Methylation kit (Zymo Research), and eluted in 20 μl. MethPrimer (40) predicted CpG islands in the first exon of both (HUMAN) Naprt and (MOUSE) Naprt and primers were designed for both methylated and unmethylated (MOUSE) Naprt and for methylated (HUMAN) Naprt (Table 2). The (MOUSE) Naprt primers were located in exon 1, 26–27 bp upstream and 78–79 bp downstream of the translation start site. The (HUMAN) Naprt primers were located in exon 1, 56–123 bp downstream of the translation start site. The methylation-specific PCR (MSP) reactions were performed on mouse gDNA using EpiMark Hot Start Taq Polymerase (New England Biolabs) on 2 μl of bisulfite-modified DNA with 200 nM of primers specific for methylated (M) or unmethylated (U) (MOUSE) Naprt. PCR reactions were heated to 95°C for 30 seconds, then 40 cycles of 95°C for 15 seconds, annealing for 30 seconds (unmethylated) or 60 seconds (methylated), and 68°C for 30 seconds, followed by a final extension of 68°C for 5 minutes. The quantitative methylation specific PCR (qMSP) reactions were performed on 100% methylated and untreated human gDNA using Power SYBR Green Master Mix (ThermoFisher) on 1 μl of bisulfite-converted gDNA with 400 nM of primers specific for methylated (HUMAN) Naprt or 250 nM of (HUMAN) ACTB primers. PCR reactions were heated to 95°C for 10 minutes, then 40 cycles of 95°C for 15 seconds, and annealing/extension for 1 minute. The percentage methylation of each human gDNA sample was calculated using the 2^ΔΔCT method. (HUMAN) Naprt methylation (Ct) was corrected for (HUMAN) ACTB (Ct) and then the fraction of methylation in untreated gDNA (if greater than zero) was calculated relative to the 100% methylated gDNA for each sample.

| Accession Number | Gene         | M or U | Forward Primers (5’-3’)                  | Reverse Primers (5’-3’)                  | Tm (°C) |
|------------------|--------------|--------|------------------------------------------|------------------------------------------|--------|
| NM_145201.5      | (HUMAN) NAPRT<sup>a</sup> | M      | GCCCACTACAAACCGGGTGGGTTCTTTGCTGGGCCGCTTTC       | GAATTCGGCGGCGGCTTTC             | 65     |
| NM_172607.3      | (HUMAN) ACTB (4I) | M      | GCCCACTACAAACCGGGTGGGTTCTTTGCTGGGCCGCTTTC       | GAATTCGGCGGCGGCTTTC             | 66     |
| NM_172607.3      | (MOUSE) Naprt<sup>b</sup> | U      | AGTGGGATTTGTCAGGTTACCCATATA              | TATTTTGGGCAGTTACCCATATA          | 59     |
| NM_172607.3      | (MOUSE) Naprt<sup>b</sup> | M      | GGGCTGGGATTTGTCAGGTTACCCATATA              | TATTTTGGGCAGTTACCCATATA          | 64     |

M, methylated sequence; U, unmethylated sequence; Tm, annealing temperature.
<sup>a</sup>Primers amplify a region 56–123 bp downstream of the translation start site in exon 1.
<sup>b</sup>Primers amplify a region 26–27 bp upstream to 78–79 bp downstream of the translation start site in exon 1.

Statistical Analyses
Statistical analyses of data were performed with SAS software, version 9.3 (SAS Institute, Cary, NC). Data were transformed to achieve normality and homogeneity of variance before statistical analysis. Outliers in the flow cytometry data sets were assessed using Prism8 (GraphPad Software). Tumor growth and size data were analyzed using mixed-effects models with repeated measures followed by a post hoc Tukey test while controlling for multiple testing. Treatment, day, and batch were considered fixed effects; cage was considered a random effect. Similarly, data for in situ and ex vivo tumor sizes on individual days and flow cytometry data were analyzed using a mixed-effects model followed by a post hoc Tukey test. Immunoblotting and NAD+ NADH assay data were analyzed for main effects of PD1 antibody (present/absent), KPT-9274 treatment (present/absent), and its interaction using a two-way factorial ANOVA (PROC GLM) and a post hoc Tukey test. Two-tailed P values <0.05 were considered statistically significant as appropriate.
Results

NAMPT and NAPRT Expression in Human and Murine Kidney Cancers

We have previously demonstrated growth attenuation of human ccRCC cell line murine xenografts in response to KPT-9274 administration (3), however we did not assess NAMPT and NAPRT expression. Herein, we evaluated these genes in archived human ccRCC tumors and normal kidneys using qPCR. No significant differences were observed in either NAMPT (Figure 1A) or NAPRT mRNA (Figure 1B) expression between normal kidneys and ccRCC tumors of grades 1–4. However, six out of 19 (31%) ccRCC tumors ranging from grades 1 to 4 had at least 25% lower NAPRT mRNA expression than the lowest-expressing normal kidney sample (Figure 1B). These low-expressing NAPRT tumors were found across all four grades of ccRCC.

We next examined the methylation status of the NAPRT promoter in normal kidney samples, ccRCC tissue, and cell lines. We used qMSP to measure the relative percentage of methylation and found that the NAPRT promoter was unmethylated in normal human kidneys. However, NAPRT was hypermethylated in all ccRCC tumors and cell lines with low expression of NAPRT mRNA, but only minimally methylated in ccRCC tumors with high expression of NAPRT (Figure 1C).

We chose the RENCA mouse model of RCC (32) to test the effects of KPT-9274 in combination with an immunotherapeutic because these cells represent a syngeneic tumor in an immunocompetent mouse, whereas “standard” immunodeficient xenografted nude mice would be ineffective for evaluating an immunotherapeutic. The RENCA tumors were found to be highly proliferative in the mouse as evidenced by Ki67 staining, associated with a relatively high level of PD-L1 expression, with PD-L2 expression confined to stromal cells (Figure 2). We next examined the expression of both (MOUSE)Nampt and (MOUSE)Naprt in RENCA tumors and normal mouse kidneys and found that RENCA tumors expressed Nampt at a similar level to that in the normal kidney, both at the protein and mRNA levels (Figure 3A). However, RENCA tumors have downregulated expression of NAPRT compared with normal kidney quantitative PCR for (HUMAN)NAMPT mRNA (corrected for PPIA, RPS13, and RNA18S5 mRNA levels). Data are means±SD (n=3–9). (B) Extracted RNA was reverse transcribed and subjected to quantitative PCR for (HUMAN) NAPRT mRNA as in (A). The red line is located below the lowest NAPRT mRNA value for normal kidneys. Data are means±SD (n=3–9). (C) The relative percentage of methylation of the (HUMAN)NAPRT promoter. Bisulfite-converted, untreated genomic DNA (gDNA) and bisulfite-converted 100% methylated gDNA from human kidneys (NHK; n=3), RCC tumors (n=8), and RCC cell lines (ACHN, Caki-1, 786-O) was analyzed by quantitative methylation-specific PCR using primers specific for methylated NAPRT sequences 56–123 bp downstream of the NAPRT translation start site, and normalized against ACTB. Samples were divided into low (blue bars) and high NAPRT expression (red bars) based on the data in (B) and from Abu Aboud et al. (3). hNARPT, (HUMAN)NAPRT.

Figure 1. (HUMAN)NAPRT is downregulated at the level of transcription, which in some renal cell carcinoma tumors is associated with high levels of promoter methylation. RNA was extracted from normal kidneys and renal cell carcinoma (RCC) tumors of grades 1–4. (A) Extracted RNA was reverse transcribed and subjected to
tissue (Figure 3A), whereas Naprt mRNA expression is more than sixfold lower in RENCA tumors versus kidneys (Figure 3B). These protein expression data are consistent with what we previously observed in human RCC cell lines (3).

We next examined whether the observed downregulation of (MOUSE)NAPRT was due to methylation of the promoter, as we have already demonstrated was present in the human ccRCC tumors. A CpG island was found in exon 1 of the Naprt gene, in a similar location to the NAPRT gene. The gDNA from RENCA cells was subjected to MSP analysis and found to contain methylated Naprt promoter sequences (data not shown). When we analyzed gDNA from three mouse kidneys using MSP, we found they contained unmethylated Naprt gDNA, whereas three RENCA tumors were found to contain both unmethylated and methylated Naprt gDNA (Figure 3C). Thus, as with human ccRCC, in RENCA tumors the downregulation of Naprt at the level of transcription is also associated with methylation of the promoter.

We measured the effect of KPT-9274 on RENCA-luc cell growth in vitro and found the viability of RENCA-luc cells was attenuated by KPT-9274 in a concentration-dependent manner (Supplemental Figure 2). This is evidence that the

Figure 3. | (MOUSE)NAPRT is downregulated at the level of transcription in RENCA tumors where the Naprt promoter is methylated. Protein and RNA were extracted from kidneys and subcutaneous RENCA tumors from untreated Balb/cJ mice. (A) Proteins were immunoblotted for NAMPT, NAPRT, and β-actin. Immunoblots are representative of at least two repeats. (B) RNA was extracted, reverse transcribed, and subjected to quantitative PCR for Nampt or Naprt mRNA (corrected for Eef2, Rpl13a, and Rn18S mRNA levels). Data are means ± SEM (n = 3 kidneys; n = 4 tumors). a, b, c P < 0.05. (C) Bisulfite-converted gDNA from Balb/cJ mouse kidneys or RENCA tumors was amplified by PCR using primers specific for either unmethylated (U) or methylated (M) sequences to amplify sequences between 26–27 bp upstream and 78–79 bp downstream of the Naprt translation start site. Data are representative of two independent PCR reactions. Neg, mouse gDNA.
loss of the NAPRT pathway through epigenetic changes not only sensitizes human RCC to NAMPT inhibition but may be directly recapitulated in this syngeneic mouse model of RCC. Based on our in vitro data as well as in vivo data on subcapsular growth of RENCA in the syngeneic mouse previously described (15), we expected that the subcutaneous RENCA tumor model would respond well to NAMPT inhibition with KPT-9274 (3).

**RENCA Tumor Growth Is Attenuated by KPT-9274**

For the in vivo model, cultured RENCA-luc cells were injected subcutaneously in BALB/cJ mice. After palpable tumors appeared (in 10 days), the mice were then treated for 21 days with either KPT-9274, anti-PD1 antibody, or a combination of both agents (see Materials and Methods). The tumors were measured with calipers every 2–3 days (Figure 4A, Supplemental Figure 3). An analysis of the tumor growth data using repeated measures over time demonstrated there were significant effects of day and treatment on tumor sizes ($P<0.001$), but no interaction between day and treatment ($P=0.98$). The combined treatment with KPT-9274 and anti-PD1 gave significantly smaller tumors than KPT-9274 alone ($P=0.001$), anti-PD1 alone ($P<0.001$), or control treatments ($P<0.001$). When tumor sizes were analyzed at each day of measurement, there was an effect of KPT-9274 on tumor growth on days 14 ($P=0.01$), 17 ($P=0.01$), 19 ($P=0.02$), and 21 ($P=0.004$) and there was also an interaction between anti-PD1 and KPT-9274 to reduce tumor growth on days 19 ($P=0.02$) and 21 ($P=0.01$; Figure 4A). No significant changes in weight were observed due to treatment, suggesting a lack of general toxicity of the treatments (Figure 4B).

The RENCA tumors were removed and measured at necropsy 21 days after starting treatment. In this analysis, tumor growth data using repeated measures over time demonstrated there were significant effects of day and treatment on tumor sizes ($P<0.001$), but no interaction between day and treatment ($P=0.98$). The combined treatment with KPT-9274 and anti-PD1 gave significantly smaller tumors than KPT-9274 alone ($P=0.001$), anti-PD1 alone ($P<0.001$), or control treatments ($P<0.001$). When tumor sizes were analyzed at each day of measurement, there was an effect of KPT-9274 on tumor growth on days 14 ($P=0.01$), 17 ($P=0.01$), 19 ($P=0.02$), and 21 ($P=0.004$) and there was also an interaction between anti-PD1 and KPT-9274 to reduce tumor growth on days 19 ($P=0.02$) and 21 ($P=0.01$; Figure 4A). No significant changes in weight were observed due to treatment, suggesting a lack of general toxicity of the treatments (Figure 4B).

The RENCA tumors were removed and measured at necropsy 21 days after starting treatment. In this analysis,

![Graph A](image1.png)

**Figure 4.** The combination of KPT-9274 and anti–programmed cell death 1 has a significant inhibitory effect on tumor growth. (A) Subcutaneous measurements of RENCA tumor growth in 10-week-old male Balb/cJ mice over the 21 days of treatment. RENCA-luc cells (250,000) were injected subcutaneously in 30% matrigel and treatments started 10 days after injection. Data are mean±SEM (n=8–10 per treatment). *$P<0.05$, **$P<0.005$ for main effect of KPT-9274. (B) The antitumor treatments did not affect mouse health as determined by body weights. Male Balb/cJ mice bearing RENCA tumors were 10 weeks old when treatments were started. Mice were weighed at the start of the treatment period and once a week thereafter. Data are means±SEM (n=9–10 per treatment). *$P<0.05$ compared to control at that time point. (C) Volume of RENCA tumors measured ex vivo at euthanasia after 21 days of treatment with either KPT-9274, anti–programmed cell death 1 antibody (PD1), or a combination of both. Data are mean±SD (n=8–10 per treatment). *$P<0.05$, **$P<0.005$. Control, isotype control.
we found there was an effect of KPT-9274 on tumor size ($P=0.001$) and evidence of a possible interaction between anti-PD1 and KPT-9274 ($P=0.088$). The combination treatment (KPT-9274 and anti-PD1) was more effective at decreasing tumor growth than either anti-PD1 alone ($P=0.001$) or KPT-9274 alone ($P=0.016$; Figure 4C).

RENCA Tumors Were Highly Necrotic
Formalin-fixed, paraffin-embedded tissue sections stained with hematoxylin and eosin were evaluated by a pathologist (K.-Y.J.). All tumor samples showed pronounced areas of geographic necrosis admixed with areas of viable tumor, which did not correlate with specific treatments (Supplemental Figure 4).

Effects of Treatments on Tumor-Infiltrating T Cell Populations
RENCA tumors were dispersed to single cells and stained to detect live CD45+ lymphocytes that were further gated on CD11b, CD19, CD3, CD4, CD8, CD25, and FoxP3 (Supplemental Figure 1, A and B). Data are expressed as a percentage of live CD45+ lymphocytes. The gating is described in Supplemental Figure 1. The infiltration of CD3lo and CD3hi cells into tumors was heterogenous in all treatment groups (Figure 5A). They had a bimodal distribution (either $<20\%$ CD3+ or $>40\%$ CD3+) which was most accentuated in the tumors from KPT-9274-treated mice. The infiltration of CD8+ cells was low in most tumors and heterogeneous with a bimodal distribution (either $<1\%$ CD8+ or $>2\%$ CD8+). This bimodal distribution was accentuated by the addition of KPT-9274 and anti-PD1, resulting in significantly more CD8+ cells in the combination treatment group compared with KPT-9274 alone (Figure 5, A and B). The infiltration of regulatory T cells was also very low ($<2\%$ of all CD45+ tumor-infiltrating lymphocytes), although they too had a bimodal distribution in different tumors ($<0.35\%$ and $>0.5\%$) which was accentuated somewhat in the combination treatment group (Figure 5A).

Tumor Expression of PAK4 and Phospho-β-Catenin Was Reduced by KPT-9274
KPT-9274 treatment of RCC cells is known to reduce PAK4 protein levels and interfere with the WNT/β-catenin signaling pathways (3). Proteins from the RENCA tumors were immunoblotted to examine levels of PAK4 and phospho-β-catenin (Figure 6, Supplemental Figure 5). We measured PAK4 and phospho-β-catenin in the tumors from 24 mice in the four treatment groups ($n=6$ per group; Supplemental Figure 5). As expected, there was an effect of KPT-9274 causing a reduction in PAK4 expression levels ($P=0.04$; Figure 6A) as well as inhibiting the phosphorylation of β-catenin ($P=0.02$; Figure 6B).

Tumor Levels of NAD+ NADH Were Reduced by KPT-9274 and Increased by PD1 Antibody
In addition to reducing levels of PAK4, KPT-9274 also inhibits the enzymatic activity of NAMPT and represses NAD biosynthesis. To confirm NAMPT inhibition in vivo, we examined the NAD+ NADH levels in RENCA tumors from mice. When we examined NAD+ NADH levels in response to each treatment individually, the NAD+ NADH levels in RENCA tumors were lower in mice treated with KPT-9274 compared to anti-PD1 ($P=0.01$; Figure 7). We also found, as in other models, that total NAD+ NADH was decreased by a main effect of KPT-9274 treatment ($P=0.02$; Figure 7). Interestingly, the NAD+ NADH levels in RENCA tumors were increased by a main effect of the anti-PD1 antibody ($P=0.02$; Figure 7).

Discussion
In this study, we found a significant interaction between the dual PAK4 and NAMPT inhibitor, KPT-9274, and an antibody against PD1 that slowed the growth of RENCA tumors in a syngeneic mouse model of renal cancer. This is in line with a recent report describing mouse models of melanoma and colon adenocarcinoma, where KPT-9274 improves the response to anti-PD1 therapy to reduce tumor growth (24). This was accompanied by a KPT-9274-driven decrease in PAK4 expression and β-catenin activation. Interestingly, although KPT-9274 reduced total NAD+ NADH as expected, there was not an overall decrease in total NAD+ NADH in the combination treatment (KPT-9274 and anti-PD1), possibly due to the inhibitory effect of KPT-9274 on energy metabolism being offset by a stimulatory effect of anti-PD1. To our knowledge, this is the first evidence that PD1 antibody therapy may be linked to increases in NAD+. Therefore, two mechanisms may be occurring independently in these tumors: first, the inhibition of (MOUSE)NAMPT activity by KPT-9274 which decreases NAD+ NADH in the tumor cells (because the RENCA cells are lacking NAPRT) and, second, the PD1 antibody may have re-engaged T cell activation and possibly increased NAD+ NADH levels even in the presence of KPT-9274, because T cells have normal levels of NAPRT. Increased NAD+ may actually enhance the antitumor T cell response (42), another salutary effect of this combination therapy.

Data from breast, colorectal, non-small cell lung, and RCC tumors (26) has suggested that combination therapies in which activated β-catenin is inhibited simultaneously with targeting PD1 can be particularly efficacious. In the RENCA model, we found the effects of PD1 blockade were unpredictable with only approximately 25% of tumors responding (Figure 4C). The effect of anti-PD1 on T cell infiltration was minimal but the combination of anti-PD1 and KPT-9274 increased CD8+ infiltration in approximately 50% of animals (Figure 5A). However, the tumors that responded to the anti-PD1 with KPT-9274 treatment were not the tumors with increased T cell infiltration (data not shown). Similarly, the tumor size response to treatment (Figure 4A, Supplemental Figure 3) did not display the same bimodal distribution observed in the infiltrated T cells (Figure 5). Thus the effectiveness of the combination treatment is possibly associated with direct antitumor effects of KPT-9274 perhaps stimulating more robust T cell activity which may be enhanced by anti-PD1. Further experiments would greatly assist in exploring these possibilities.

NAMPT transfers a phosphoribosyl residue from 5-phosphoribosyl-1-pyrophosphate to nicotinamide which produces nicotinamide mononucleotide. Nicotinamide mononucleotide adenyllytransferase converts nicotinamide mononucleotide into NAD+ (43). An alternative NAD biosynthesis
Figure 5. | T cell infiltration into RENCA tumors showed a bimodal distribution in mice treated with KPT-9274 or KPT-9274 plus anti-PD1. (A) CD3+, CD4+, CD8+, and regulatory T cell (Tregs) infiltration into syngeneic RENCA tumors. Data are individual tumor data points with mean±SD. Statistically determined outliers for CD8+ cells in the KPT-9274–treated mice (3.8%, 8.1%) and in the anti-PD1–treated mice (31.2%) were omitted to enable clarity of presentation. (B) Representative two-dimensional contour plots (with outliers) for CD4+ and CD8+ T cells in one tumor from each treatment group.
pathway employs the three step Preiss–Handler pathway that starts with NAPRT acting on nicotinic acid to generate nicotinic acid mononucleotide, which is then converted to nicotinic acid adenine dinucleotide and subsequently to NAD\(^1\) (44,45). This pathway can also salvage NAD\(^1\) from nicotinamide by using a gut bacterial nicotinamidase to convert nicotinamide to nicotinic acid (13). A subset of non-small cell lung carcinoma, small cell lung carcinoma, breast cancer, pancreatic cancer, glioma, and fibrosarcoma cell lines have epigenetic downregulation of the NAPRT promoter, which correlates with low NAPRT expression in these lines (14,46), as we found in a subset of human ccRCC patients (Figure 1) and RENCA cells (Figure 3). In these patients, NAMPT inhibitors may be particularly efficacious at inhibiting tumor growth because one salvage pathway for NAD biosynthesis is severely reduced. The supplementation of nicotinic acid to patients can mitigate the potential toxic side effects of NAMPT inhibition in nontarget tissues that still express NAPRT, while the tumor cells that have reduced NAPRT expression will still be affected by the NAMPT inhibitor despite nicotinic acid supplementation (14). Low expression of NAPRT (\(\leq 7.62\) fragments per kilo-base of transcript per million) in renal cancer is an unfavorable prognostic marker (https://www.proteinatlas.org/ENSG00000147813-NAPRT/pathology/tissue/renal+cancer).

This has not been found in other malignancies and has not been reported elsewhere, and the data suggest a personalized-medicine approach in which those patients with RCC who are identified to have low expression of NAPRT mRNA associated with methylation of the NAPRT promoter (see Figure 1) would likely be particularly appropriate candidates for KPT-9274 therapy with nicotinic acid supplementation.

A high level of variation in tumor growth rates was observed in the control mice, despite these being clonal tumors in syngeneic hosts. In all treatment groups, there were mice whose tumors grew very little over the 21-day treatment period (Supplemental Figure 3), whereas some mice grew very large tumors in the anti-PD1 and control groups only. The innate immune system is capable of both promoting tumor growth as well as inhibiting tumor growth (47). If the combination treatment KPT-9274 and

Figure 6. | KPT-9274 decreased phosphorylation of β-catenin and total PAK4 expression. Protein was extracted from RENCA tumors in mice treated with PD1 antibody (anti-PD1), KPT-9274, or a combination of both and was immunoblotted for (A) PAK4, (B) phospho-β-catenin (P-β-catenin), and β-actin. Image quantification of phospho-β-catenin and PAK4 expression, each corrected for β-actin, are underneath a representative immunoblot from one tumor per mouse. Data are means±SEM (n=6). \(^{a,b}P<0.05\).

Figure 7. | KPT-9274 reduces and anti-PD1 increases NAD+\(\text{NADH}\) concentrations in tumors. RENCA tumors from Balb/cj mice were harvested 12–18 hours after the last dose of either KPT-9274 or vehicle and subjected to assays of total NAD+\(\text{NADH}\) as described in Materials and Methods. Mice treated with KPT-9274 had lower total NAD+\(\text{NADH}\) in RENCA tumors than mice treated with anti-PD1. Data are means±SD (n=7). \(^{a,b}P<0.05\). NAD+\(\text{NADH}\), total oxidized (NAD+) and reduced β-Nicotinamide adenine dinucleotide (NADH).
anti-PD1 is inhibiting tumor growth via recruitment of more tumor-inhibitory than tumor-promoting elements of the immune system, this suggests that there are stochastic events which control the immune response to tumors that we may not be able to measure or easily control. However, we can conclude that the combination treatment did not cooperate to recruit more T cells to the tumors in our experiments.

In summary, we have extended our previous work on a dual PAK4/NAMPT inhibitor in kidney cancer to show that therapy with this drug in combination with the anti-PD1 is more effective at inhibiting growth of the tumors when compared with the single therapies. These data indicate that this combination should be evaluated in patients who are unresponsive to immune CPI alone; our work may thus broaden the populations that show a robust response with these novel antibody treatments.

Acknowledgments
We thank Lauren Hirao for assistance with planning the flow cytometry experiments.

Author Contributions
O. Abu Aboud, K. Anderson, J. Modiano, W. Senapedis, J. Trott, and R. Weiss conceptualized the study; O. Abu Aboud, K. Jen, K. Kim, B. McLaughlin, and J. Trott were responsible for formal analysis; Y. Landesman, W. Senapedis, J. Trott, and R. Weiss were responsible for funding acquisition; O. Abu Aboud, H. Chang, B. McLaughlin, and J. Trott were responsible for investigation; O. Abu Aboud, K. Anderson, B. McLaughlin, J. Modiano, and J. Trott were responsible for methodology; O. Abu Aboud, B. McLaughlin, J. Modiano, J. Trott, and R. Weiss wrote the original draft; O. Abu Aboud, K. Anderson, H. Chang, K. Jen, K. Kim, Y. Landesman, B. McLaughlin, J. Modiano, W. Senapedis, J. Trott, and R. Weiss reviewed and edited the manuscript; E. Baloglu, R. Pili, and R. Weiss were responsible for resources; H. Chang conducted immunohistochemistry experiments; Y. Landesman and W. Senapedis provided advice; R. Weiss provided supervision.

Disclosures
This work was in part supported by grants from Dialysis Clinics Incorporated (DCI), but DCI had no influence on the experiments, data collection, or manuscript writing. E. Baloglu, H. Chang, Y. Landesman, and W. Senapedis were employees of Karyopharm Therapeutics while the work was being carried out and report having patent WO 2017031213 issued, but they did not influence the experiments or conclusions of the paper. Karyopharm provided KPT-9274 and an unrestricted gift for purchase of some reagents. W. Senapedis has stock and options in Karyopharm Therapeutics Inc. O. Abu Aboud, K. Anderson, K. Jen, K. Kim, B. McLaughlin, J. Modiano, R. Pili, J. Trott, and R. Weiss have nothing to disclose.

Funding
This work was supported by National Institutes of Health (NIH) National Cancer Institute (NCI) grant 1R03CA181837-01, NIH National Institute of Diabetes and Digestive and Kidney Diseases grant 1R01DK082690-01A1, and the Medical Service of the US Department of Veterans Affairs, all to R. Weiss. This work was also supported in part by DCI (to J. Trott and R. Weiss). K. Anderson was supported by the NCI Ruth L. Kirschstein National Research Service Award F30 CA195973. J. Modiano was supported by the Perlman Chair in Animal Oncology. This project was also supported by the University of California Davis Flow Cytometry Shared Resource Laboratory with funding from NCI grant P30 CA093373 (Cancer Center) and NIH National Center for Research Resources grant C06-R212088. A nonrestricted gift for research purposes was provided by Karyopharm Therapeutics.

Supplemental Material
This article contains the following supplemental material online at http://kidney360.asnjournals.org/lookup/suppl/doi:10.34067/KID.0000282019/-/DCSupplemental.

Supplemental Figure 1. Gating strategy for flow cytometry.
Supplemental Figure 2. RENCA-luc cell viability is reduced by KPT-9274 in a dose-dependent manner.
Supplemental Figure 3. Subcutaneous measurements of tumor growth of RENCA-luc cells in 10- week-old male Balb/cj mice over the 21 days of treatment.
Supplemental Figure 4. Sections of Balb/c RENCA tumors excised 21 days after treatment with combinations of KPT-9274 and/or anti-PD1 antibody.
Supplemental Figure 5. KPT-9274 decreased phosphorylation of β-catenin and total PAK4 expression.

References
1. Gong J, Chehrazi-Kaffie A, Reddi S, Salgia R: Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: A comprehensive review of registration trials and future considerations. J Immunother Cancer 6: 8, 2018
2. Ross K, Jones RJ: Immune checkpoint inhibitors in renal cell carcinoma. Clin Sci (Lond) 131: 2627–2642, 2017
3. Abu Aboud O, Chen CH, Senapedis W, Baloglu E, Argueta C, Weiss RH: Dual and specific inhibition of NAMPT and PAK4 By KPT-9274 decreases kidney cancer growth. Mol Cancer Ther 15: 2119–2129, 2016
4. Rane C, Senapedis W, Baloglu E, Landesman Y, Crochiere M, Das-Gupta S, Minden A: A novel orally bioavailable compound KPT-9274 inhibits PAK4, and blocks triple negative breast cancer tumor growth. Sci Rep 7: 42555, 2017
5. Mitchell SK, Larkin K, Grieselhuber NB, Lai TH, Canton M, Orwick S, Sharma P, Asemwah Y, Zhang P, Goettl VM, Beaver L, Mims A, Pauduvalli VK, Blachly JS, Lehman A, Harrington B, Henderson S, Breithbach JT, Williams KE, Dong S, Baloglu E, Senapedis W, Kirschner K, Sampath D, Lapalombella R, Byrd JC: Selective targeting of NAMPT by KPT-9274 in acute myeloid leukemia. Blood Adv 3: 242–255, 2019
6. Li N, Lopez MA, Linares M, Kumar S, Oliva S, Martinez-Lopez J, Xu L, Xu Y, Perini T, Senapedis W, Baloglu E, Shammas MA, Hunter Z, Anderson KC, Teon SP, Munshi NC, Fulciniti M: Dual PAK4-NAMPT inhibition impacts growth and survival, and increases sensitivity to DNA-damaging agents in waldenström macroglobulinemia. Clin Cancer Res 25: 369–377, 2019
7. Aboukameel A, Muqbil I, Senapedis W, Baloglu E, Landesman Y, Shacham S, Kaufman M, Philip PA, Mohammad RM, Azmi AS: Novel p21-activated kinase 4 (PAK4) allosteric modulators overcome drug resistance and stemness in pancreatic ductal adenocarcinoma. Mol Cancer Ther 16: 76–87, 2017
8. Fulciniti M, Martinez-Lopez J, Senapedis W, Oliva S, Lakshmi Bandi R, Amodio N, Xu Y, Szalat R, Gulla A, Samur MK, Roccaro A, Linares M, Cea M, Baloglu E, Argueta C, Landesman Y, Shacham S, Liu S, Scheneone M, Wu SL, Karger B, Prabhala R, Anderson KC, Munshi NC: Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma. Blood 129: 2233–2245, 2017
9. Jiang YY, Lin DC, Mayakonda A, Hazawa M, Ding LW, Chien WW, Xu L, Chen Y, Xiao JF, Wang MR, Koefler HP: Targeting super-enhancer-associated oncogenes in oesophageal squamous cell carcinoma. Gut 66: 1358–1368, 2017
10. Takao S, Chien W, Madan V, Lin DC, Ding LW, Sun QY, Mayakonda A, Sudo M, Xu L, Chen Y, Jiang YY, Gery S, Lill M, Park E, Senapedis W, Baloglu E, M¨uschen M, Koefler HP:
Targeting the vulnerability to NAD+ depletion in B-cell acute lymphoblastic leukemia. Leukemia 32: 616–625, 2018

11. London C, Brown M, Warrn E, Schuh E, Senapedis WT, Arqueta C, Kashayp T, Chang H, Ellis J, Shacham M, Baloglu E, Abstract LB-308: KPT-9274 inhibits cellular NAD and synergizes with doxorubicin to treat dogs with lymphoma. Cancer Res 77: LB-308, 2017

12. Naing LL, Leong S, Pichavian MJ, Razak AR, Mahipal A, Berlin J, Cho D, Baloglu E, Ellis J, Meade J, Kauflman M, Shacham S, Senapedis W: 374PDA first in human phase 1 study of KPT-9274, a first in class dual inhibitor of PAK4 and NAMPT, in patients with advanced solid malignancies or NHL. Ann Oncol 28(Suppl 5), 2017. doi:10.1093/annonc/mdx367.008

13. Bogan KL, Brenner C: Nicotinic acid, nicotinamide, and nicotinamide riboside: A molecular evaluation of NAD precursor in human nutrition. Annu Rev Nutr 28: 115–130, 2008

14. Shames DS, Elkins K, Walter K, Holcomb T, Du P, Mohl D, Xiao Y, Khoo V, Grünwald V, Gillessen S, Horwich A; ESMO Guidelines Committee: Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 30: 706–720, 2019

15. Escudier B, Porta C, Schmieder M, Rioux-Leclercq N, Bex A, Khoo V, Green M, Chang H, Fulton N, Larson RA, Odenike O, Artz AS, Bishop MR, Godley LA, Thirman MJ, Kosuri S, Churpek CE, Curran E, Pettit K, Stock W, Liu H: A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia. J Hematol Oncol 11: 4, 2018

16. Li Y, Shao Y, Tong Y, Shen T, Zhang J, Li Y, Gu H, Li F: Nucleocytoplasmatic shuttling of PAK4 modulates β-catenin intracellular translocation and signaling. Biochim Biophys Acta 1823: 465–475, 2012

17. Clevers H: Wnt/β-catenin signaling in development and disease. Cell 127: 469–480, 2006

18. Liao DJ, Thakur A, Wu J, Biliran H, Sarkan FH: Perspectives on c-Myc, Cyclin D1, and their interaction in cancer formation, progression, and response to chemotherapy. Crit Rev Oncog 13: 93–158, 2007

19. Nekrasova T, Minden A: PAK4 is required for regulation of the cell-cycle regulatory protein p21, and for control of cell-cycle progression. J Cell Biol 112: 1795–1806, 2000

20. Callow MG, Clairvoyant F, Zhu S, Schwyer B, Whyte DB, Bischoff JR, Jalal B, Smeal T: Requirement for PAK4 in the anchorage-independent growth of human cancer cell lines. J Biol Chem 277: 550–558, 2002

21. Kimmelman AC, Hezel AF, Aguirre AJ, Zheng H, Paik JH, Ying H, Li X, Weiss RH: Neoplastic transformation of porcine mammary epithelial cells in vitro and tumor formation in vivo. BMC Cancer 15: 562, 2015

22. Dewey RC: Neoplastic transformation of porcine mammary epithelial cells in vitro and tumor formation in vivo. Kidney Int 92: 922–933, 2017

23. Li LC, Daiya R: Methylation of 5-hydroxymethylcytosine. Trends Biochem Sci 36: 37–43, 2011

24. Preiss J, Handler P: Biosynthesis of diphosphopyridine nucleotide. I. Enzymatic aspects. J Biol Chem 253: 883–889, 1978

25. Preiss J, Handler P: Biosynthesis of diphosphopyridine nucleotide. II. Enzymatic aspects. J Biol Chem 253: 890–896, 1978

26. Tateishi K, Wakimoto H, Iafrate AJ, Tanaka S, Loebel F, Lelic N, Wiederschain D, Bedel O, Deng G, Zhang B, He T, Shi X, Gerszten RE, Zhang Y, Yeh J, Curry WT, Zhao D, Sundaram S, Preiss J: Anti-tumor immunity. 523: 231–235, 2018

27. Murphy GP, Hrushevsky WJ: A murine renal cell carcinoma. J Natl Cancer Inst 50: 1013–1025, 1973

28. Salup RR, Herberman RB, Willrout RH: Role of natural killer activity in development of spontaneous metastases in murine renal cancer. J Urol 134: 1243–1241, 1985

29. Tracz A, Mastr i M, Lee CR, Pili R, Ehsan JM: Modeling spontaneous metastatic renal cell carcinoma (mRCC) in mice following nephrectomy. J Vis Exp 86: e51485, 2014

30. Escudier B, Porta C, Schmieder M, Rioux-Leclercq N, Bex A, Khoo V, Grünwald V, Gillessen S, Horwich A; ESMO Guidelines Committee: Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 30: 706–720, 2019

31. Wang YY, Werner H, Green M, Chang H, Fulton N, Larson RA, Odenike O, Artz AS, Bishop MR, Godley LA, Thirman MJ, Kosuri S, Churpek CE, Curran E, Pettit K, Stock W, Liu H: A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia. J Hematol Oncol 11: 4, 2018

32. Abbasi J, Abu-Alli J, Abboud O, Yusuf R, Khaled J, Shacham S, Stewart B, Berryhill G, Uzal F, Hovey RC, Chen CH, Anderson K, Graef A, Sarver AL, Modiano JF, Weiss RH: Inhibiting tryptophan metabolism enhances interferon therapy in kidney cancer. Oncotarget 7: 66540-66557, 2016

33. Trott JF, Hwang VJ, Ishimaru T, Chmiel KJ, Zhou JX, Shim K, Stewart BJ, Mahjoub MR, Jen KY, Barupal DK, Li X, Weiss RH: Arginine reprogramming in ADPKD results in arginine-dependent cystogenesis. Am J Physiol Renal Physiol 315: F1855–F1868, 2018

34. Schuster S, Penke M, Gorski T, Petzold-Quinke S, Damm G, Gebhardt R, Kiess W, Garten A: Resveratrol Differentially Regulates NAMPT and SIRT1 in Hepatocarcinoma Cells and Primary Human Hepatocytes. PLoS One 9: e91045, 2014

35. Wang LF, Wang XN, Huang CC, Hu L, Xiao YF, Guan XH, Qian YS, Deng KY, Xin HB: Inhibition of NAMPT aggravates high fat diet-induced hepatic steatosis in mice through regulating Sirt1/AMPKα/SREBP1 signaling pathway. Lipids Health Dis 16: 82, 2017

36. Bowson-Hoelle AR, Manjari N, Trott JF, Cardiff RF, Borowsky AD, Hovey RC: Neoplastic transformation of porcine mammary epithelial cells in vitro and tumor formation in vivo. BMC Cancer 15: 562, 2015

37. Dupasquier S, Delmarchelle AS, Marbaix E, Cosyns JP, Courtoy PJ, Pierreux CE: Validation of housekeeping gene and impact on normalized gene expression in clear cell renal cell carcinoma: critical reassessment of YBX3/ZONAJI/CSDA expression. BMC Mol Biol 15: 9, 2014

38. Inoue H, Hwang SH, Weckslter AT, Hammad BD, Weiss RH: Sorafenib attenuates P21 in kidney cancer cells and augments cell death in combination with DNA-damaging chemotherapy. Cancer Biol Ther 12: 827–836, 2011

39. Hwang VJ, Zhou X, Chen X, Trott J, Abu-Alli O, Shim K, Dionne LK, Chmiel KJ, Chmielewski W, Baloglu E, Mahjoub MR, Li X, Weiss RH: Anticystogenic activity of a small molecule PAK4 inhibitor may be a novel treatment for autosomal dominant polycystic kidney disease. Kidney Int 92: 922–933, 2017

40. Li LC, Dahiya R: MethyPrimer: Designing primers for methylation PCR. Bioinformatics 18: E127–E131, 2002
Nigim F, Koerner MVA, Ho Q, Fisher DE, Roider EM, Kemeny LV, Samuels Y, Flaherty KT, Batchelor TT, Chi AS, Cahill DP: Extreme vulnerability of IDH1 mutant cancers to NAD\(^+\) depletion. Cancer Cell 28: 773–784, 2015

47. Hagerling C, Casbon AJ, Werb Z: Balancing the innate immune system in tumor development. Trends Cell Biol 25: 214–220, 2015

Received: October 16, 2019 Accepted: March 12, 2020

J.F.T. and O.A.A. contributed equally to this work.

Present address: Dr. Katie L. Anderson, North Carolina State University College of Veterinary Medicine, Raleigh, North Carolina.
**Supplemental Data Figure Legends**

**Supp Fig. 1.** Gating strategy for flow cytometry. Tumors cells were dispersed and strained through a 100 µm filter then stained with Aqua Zombie, followed by anti-CD45-Alexa Fluor 700 (clone 30-F11), anti-CD11b-APC/Fire 750 (clone M1/70), anti-CD4-PE (clone RM4-4), anti-CD19-FITC (clone 6D5), anti-CD25-PE/Cy7 (clone PC61.5), anti-CD3ε-Brilliant Violet 421 (clone 145-2C11) and anti-CD8a-Brilliant Violet 605 (clone 53-6.7). Cells were then fixed and stained for intracellular FoxP3 using anti-FoxP3-APC (clone 3G3). One spleen was processed alongside each group of tumors. Forward and side scatter detector voltage settings were selected based on the position of CD3+ or CD45+ T cell staining. Splenocytes were used as a guide for setting up the machine, guiding gating strategy and detector voltages. There was a significant amount of heterogeneity in the tumor samples, thus a logarithmic setting was used for side scatter in order to display the full range of SSC signals. The CD45+ cells were clearly defined. Thus we determined where the position of putative leukocytes were in the tumor cell scatter plot through back gating analysis of CD45+ staining. Once we identified leukocytes in the tumor cell scatter plot we chose an appropriate forward scatter detector voltage. Our gating strategy was anchored on AlexaFluor700-CD45+ and all subpopulation percentages are expressed as a % of CD45+. A) The gating strategy used for the splenocytes. First we applied a size gate to select for lymphocytes, another size gate to select single cells, followed by a viability gate (Aqua Zombie negative) to exclude dead cells. Live (Aqua Zombie-) cells were gated for CD45+ and these were split into CD11b+ and CD11b- cells. The CD11b+ cells were gated for CD19 and the CD19- cells were further gated to be CD3- based on splenocyte CD3 staining/gating.
The CD11b- cells (T&B cells) were gated for CD3-CD19+ (b-cells) and CD3+CD19- cells. The CD3+CD11b-CD19- cells were gated into CD4+CD8- and CD4-CD8+ T cells. The CD4+ T cells were then gated for CD25 and FoxP3 to select CD4+CD25+FoxP3+ cells (Tregs). B) The gating strategy used for the splenocytes was applied to the tumor cells with the following differences. A time gate was initially applied to exclude any electronic noise (not shown, not required for all tumors). The color dot plots show the lymphocyte gate on the forward vs side scatter plot with back gating of CD45+ live cells, CD45+CD11b-CD19-CD3+CD4+ live cells, CD45+CD11b-CD19-CD3+CD8+ live cells, CD45+CD11b+CD19- macrophages and CD45+CD11b-CD3-CD19+ b cells. The detection of CD3+ cells in tumor samples had poor resolution and varied between tumors. Thus BV421-CD3<sup>lo</sup> and BV421-CD3<sup>hi</sup> cells were all classified as CD3+, and this gate was determined based on splenocyte gating and other markers like CD19.

**Supp Fig. 2.** RENCA-luc cell viability is reduced by KPT-9274 in a dose-dependent manner. RENCA-luc cells were plated in 96-well plates (1.4x10<sup>3</sup>/well), and the next day were treated with varying doses of KPT-9274 for three days then assayed using MTT (viability). Data are means ± SEM (n=8) and representative of three experiments. *P<0.02 compared with 0 µM (Students t-test).

**Supp Fig. 3.** Subcutaneous measurements of tumor growth of RENCA-luc cells in 10-week-old male Balb/cJ mice over the 21 days of treatment. RENCA-luc cells (250,000) were injected subcutaneously in 30% matrigel and treatments started 10 days after injection. Each line is the growth of one tumor. PD1 = anti-mouse PD1 antibody. Control = isotype control.
Supp Fig. 4. Sections of Balb/c RENCA tumors excised 21 days after treatment with combinations of KPT-9274 and/or anti-PD1 antibody. Tissues were formalin-fixed and paraffin-embedded, sectioned and stained with hematoxylin and eosin. Sections of the tumors demonstrated extensive areas of necrosis admixed with sheets of viable tumor cells.

Supp Fig. 5. KPT-9274 decreased phosphorylation of β-catenin and total PAK4 expression. Protein was extracted from RENCA tumors in mice treated with PD1 antibody (Anti-PD1), KPT-9274 or a combination of both (n=6 per treatment group). Each lane contains the protein from one tumor/mouse. Proteins were immunoblotted for phospho (P)-β-catenin, PAK4 and β-actin. Vehicle, mice received KPT-9274 vehicle.
Supp Figure 2
Supp Figure 5

[Image: Western blot images showing the expression levels of P-β-catenin (Ser 675), PAK4, and β-actin under different conditions. Each lane represents a different treatment condition or control, with Mouse numbers ranging from 1 to 24. The treatments include Control, Anti-PD1, KPT-9274, and KPT-9274/PD1.]